Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDQuarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2024 | 1 | -$3.33 | -$3.33 | -$3.33 |
Q2 2024 | 1 | -$3.20 | -$3.20 | -$3.20 |
Q3 2024 | 1 | -$3.15 | -$3.15 | -$3.15 |
Q4 2024 | 3 | -$2.99 | -$2.76 | -$2.88 |
Q1 2025 | 1 | -$2.70 | -$2.53 | -$2.62 |
Q2 2025 | 1 | -$2.57 | -$2.57 | -$2.57 |
Q3 2025 | 1 | -$2.52 | -$2.52 | -$2.52 |
Q4 2025 | 1 | -$2.27 | -$2.27 | -$2.27 |
Q1 2026 | 1 | -$2.28 | -$2.28 | -$2.28 |
Q2 2026 | 1 | -$2.37 | -$2.37 | -$2.37 |
Q3 2026 | 1 | -$2.45 | -$2.45 | -$2.45 |
Q4 2026 | 1 | -$1.77 | -$1.77 | -$1.77 |
Kezar Life Sciences, Inc. last posted its earnings results on Tuesday, November 12th, 2024. The company reported $-2.78 earnings per share for the quarter, topping analysts' consensus estimates of $-3.03 by $0.25. The company had revenue of 0 for the quarter and had revenue of 7.00 M for the year. Kezar Life Sciences, Inc. has generated $-1 earnings per share over the last year ($-1.4 diluted earnings per share) and currently has a price-to-earnings ratio of -5.06. Kezar Life Sciences, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, March 12th, 2025 based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
11/12/2024 | Q3 2024 | -$3.03 | -$0.28 | 2.75 | $800,000 | $0 |
08/13/2024 | Q2 2024 | -$3.20 | -$2.96 | 0.24 | $750,000 | $0 |
05/09/2024 | Q1 2024 | -$3.40 | -$0.30 | 3.1 | $0 | |
03/14/2024 | Q4 2023 | -$3.90 | -$0.44 | 3.46 | $-5,428,000 | |
11/13/2023 | Q3 2023 | -$3.60 | -$0.32 | 3.28 | $166,667 | $7.00 M |
08/10/2023 | Q2 2023 | -$3.30 | -$0.34 | 2.96 | $0 | |
05/11/2023 | Q1 2023 | -$2.80 | -$0.28 | 2.52 | $0 | |
03/14/2023 | Q4 2022 | -$2.40 | -$0.23 | 2.17 | $0 | |
11/10/2022 | Q3 2022 | -$2.60 | -$0.23 | 2.37 | $0 | |
08/11/2022 | Q2 2022 | -$2.70 | -$0.25 | 2.45 | $0 | |
05/12/2022 | Q1 2022 | -$2.90 | -$0.27 | 2.63 | $0 | |
03/17/2022 | Q4 2021 | -$2.90 | -$0.25 | 2.65 | $0 | |
11/09/2021 | Q3 2021 | -$2.60 | -$0.28 | 2.32 | $0 | |
08/12/2021 | Q2 2021 | -$2.60 | -$0.25 | 2.35 | $0 | |
05/12/2021 | Q1 2021 | -$2.40 | -$0.25 | 2.15 | $0 | |
03/11/2021 | Q4 2020 | -$2.50 | -$0.22 | 2.28 | $0 | |
11/05/2020 | Q3 2020 | -$2.10 | -$0.23 | 1.87 | $0 | |
08/06/2020 | Q2 2020 | -$0.22 | $0 | |||
05/07/2020 | Q1 2020 | -$4.00 | -$0.20 | 3.8 | $0 | |
03/12/2020 | Q4 2019 | -$5.60 | -$0.50 | 5.1 | $0 |
Kezar Life Sciences, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, March 12th, 2025 based off last year's report dates.
In the previous quarter, Kezar Life Sciences, Inc. (:KZR) reported $-2.78 earnings per share (EPS) to beat the analysts' consensus estimate of $-3.03 by $0.25.
The conference call for Kezar Life Sciences, Inc.'s latest earnings report can be listened to online.
The conference call transcript for Kezar Life Sciences, Inc.'s latest earnings report can be read online.
Kezar Life Sciences, Inc. (:KZR) has a recorded annual revenue of $7.00 M.
Kezar Life Sciences, Inc. (:KZR) has a recorded net income of $7.00 M. Kezar Life Sciences, Inc. has generated $-1.4 earnings per share over the last four quarters.
Kezar Life Sciences, Inc. (:KZR) has a price-to-earnings ratio of -5.06 and price/earnings-to-growth ratio is -5.08.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED